



Pigment Epithelial Detachment Outcomes with Aflibercept 8 mg versus Aflibercept 2 mg in the PULSAR trial: A 96-Week Post hoc Analysis

Michael Singer,¹ on behalf of the PULSAR study investigators

¹University of Texas Health Science Center, San Antonio, TX, USA

Financial Disclosures

- **Michael Singer:** Consultant for Aerie, Allegro, Alimera, Allergan, Eyepoint, Genentech, Kodiak, Novartis, Regeneron Pharmaceuticals, Inc., and Santen; speaker bureau member for Allergan, Eyepoint, Genentech, Novartis, Regeneron Pharmaceuticals, Inc., and Spark; contracted research with Aerie, Allegro, Allergan, Alimera, DRCR, Genentech, Icon, Ionis, Kalvista, Kodiak, Novartis, Opthea, Optos, Regeneron Pharmaceuticals, Inc., Santen, Senju, Sydnexis, and Ribomic; and equity in Aviceda, Nanoscope, and Inflammasome
- The PULSAR study (NCT04423718) was sponsored by Bayer AG (Leverkusen, Germany) and co-funded by Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA). The sponsor participated in the design and conduct of the study, analysis of the data, and preparation of this presentation
- Study disclosures: This study includes research conducted on human patients. Institutional Review Board approval was obtained prior to study initiation
- Medical writing support, under the direction of the authors, was provided by ApotheCom and funded by Bayer Consumer Care AG (Basel, Switzerland), in accordance with Good Publication Practice (GPP) guidelines (*Ann Intern Med.* 2022;175:1298–1304)

PULSAR: 96-Week, Multicenter, Double-masked Study in Patients with Treatment-naïve nAMD


Patients were randomly assigned (1:1:1) to receive aflibercept 8q12 (n=335), 8q16 (n=338), or 2q8 (n=336) each after 3 monthly injections

At W48, treatment with aflibercept 8 mg demonstrated non-inferior BCVA gains with extended dosing intervals versus aflibercept 2 mg in patients with nAMD,¹ with no new safety signals


At W96, treatment with aflibercept 8 mg maintained improvements in visual and anatomic outcomes with extended dosing intervals, demonstrating long-term efficacy with no new safety signals

Absolute CRT (observed values)

3 monthly active injections at BL, W4, and W8




Patients with no IRF and SRF



	Mean number of injections from BL	
	2 mg	8 mg
W48	6.9	5.6
W96	12.8	9.0

FAS: 2q8 n=336; 8q12 n=335; 8q16 n=338 (at BL). ^aLS mean values (post-ICE data were censored). ^bLS means were generated using MRMM, with BL CRT measured as a covariate; fixed factors included treatment group (aflibercept 2q8, 8q12, 8q16), visit, and stratification variables (geographic region [Japan vs Rest of World] and BL BCVA [<60 vs ≥ 60]); and interaction terms were included for BL and visit and for treatment and visit. 2q8, aflibercept 2 mg every 8 weeks; 8q12, aflibercept 8 mg every 12 weeks; 8q16, aflibercept 8 mg every 16 weeks; BCVA, best-corrected visual acuity; BL, baseline; CRT, central subfield retinal thickness; FAS, full analysis set; ICE, intercurrent event; LS, least squares; MRMM, mixed model for repeated measures; nAMD, neovascular age-related macular degeneration; W, week. ¹Lanzetta P, et al. *Lancet*. 2024;403:1141–1152.

Objective and Methods



Objective:

- Evaluate the impact of aflibercept 8 mg and 2 mg on PED outcomes in the PULSAR trial

Definition:

- PED is characterized by the separation of the RPE from the Bruch's membrane
- Neovascular lesion complex (LC) is comprised of the serous (sub-RPE fluid) and fibrovascular component of the PED


Outcomes:

- Presence and location of serous component of PED and neovascular LC through Week 96^a
- Thickness of serous component of PED and neovascular LC in patients with serous component of PED and neovascular LC with involvement of the foveal center

Presence and Location of PED at Baseline	2q8 (n=336)	8q12 (n=335)	8q16 (n=338)	All 8 mg (n=673)
Presence of serous component of PED, n (%)	164 (48.8)	171 (51.0)	171 (50.6)	342 (50.8)
Serous component of PED with involvement of foveal center, n (%)	29 (8.6)	42 (12.5)	36 (10.7)	78 (11.6)
Neovascular LC with involvement of foveal center, n (%)	299 (89.8)	299 (90.1)	296 (88.6)	595 (89.3)


^aAssessed using SD-OCT at Wisconsin Reading Center. LC, lesion complex; PED, pigment epithelial detachment, RPE, retinal pigment epithelium.

Patients with Serous Component of PED Through Week 96




Lower proportion of patients had serous component of PED with aflibercept 8 mg than with aflibercept 2 mg through Week 96

Reduction of Proportion of Patients with Serous Component of PED at Key Timepoints




- The proportion of patients with serous component of PED decreased by 29.2%, 37.5%, and 36.7% in the 2q8, 8q12, and 8q16 groups, respectively, from BL to Week 96

Thickness of Serous Component of PED Involving the Foveal Center Through Week 96



- **Marked reductions in thickness of the serous component of PED** involving the foveal center were achieved with aflibercept 8 mg and 2 mg at **Week 12**
- **Reductions in thickness of the serous component of PED** involving the foveal center were **sustained** through **Week 96**


Reductions in Thickness of Serous Component of PED Involving the Foveal Center at Key Timepoints




Marked reductions in thickness of the serous component of PED involving the foveal center at Week 12 were sustained through Week 96 in the aflibercept 8q12, 8q16, and 2q8 groups

Patients with Neovascular LC Involving the Foveal Center Through Week 96

Patients with Neovascular LC Involving the Foveal Center



Mean Neovascular LC Thickness




- **Decrease** in proportion of **patients with neovascular LC** involving the foveal center, from **BL to Week 96**, was comparable in the 8 mg and 2 mg treatment groups
- **Reduction** in mean thickness of neovascular LC involving the foveal center, achieved with **aflibercept 8 mg and 2 mg** at **Week 12**, was **sustained at Weeks 48 and 96**

Conclusions

- A **lower proportion of patients** treated with **aflibercept 8 mg** than with aflibercept 2 mg had **serous component of PED through Week 96**
- **Marked reductions in thickness of serous component of PED** involving the foveal center were achieved in the aflibercept 8q12, 8q16, and 2q8 groups
- **Decrease** in proportion of **patients with neovascular LC** involving the foveal center, from BL to Week 96, was **comparable in the 2 mg and 8 mg** treatment groups
- Moderate reductions in mean neovascular LC thickness were seen across all 3 treatment groups
- All **improvements in PED outcomes were observed early at Week 12** and **maintained through Week 96**, with **fewer injections of aflibercept 8 mg** than aflibercept 2 mg

Patients with Serous Component of PED



Patients with Neovascular LC Involving the Foveal Center

